Juha Ranti

6PUBLICATIONS
35CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)HaematologyTransplantation immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 18, 2026
A functional prognostic model predicts progression-free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax.

|Mar 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Moritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht

|Sep 19, 2025
Real-world study on patient characteristics, treatment patterns and outcomes for treated patients with chronic lymphocytic leukemia during 2013-2022 in Finland.

Juha Ranti, Sanaz Jamalzadeh, Eleonora Mäkelä

|Apr 18, 2025
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Carsten U Niemann, Julie Dubois, Kazem Nasserinejad

|Sep 09, 2022
Clinical and healthcare burden of disease associated with cytomegalovirus in allogeneic hematopoietic stem cell transplantation - A retrospective single-center study.

Juha Ranti, Katariina Perkonoja, Tommi Kauko

|Sep 21, 2018
Early CD8+-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT.

Juha Ranti, Samu Kurki, Urpu Salmenniemi

Pageof 1

Frequent Collaborators

3 joint publications

Carsten Utoft Niemann

3 joint publications

Caspar da Cunha-Bang

3 joint publications

Mark-David Levin

3 joint publications

Arnon P Kater